BridgeBio Pharma, Inc. has announced the pricing of its initial public offering of 20,500,000 shares of its common stock at a price to the public of $17.00 per share, as detailed in the company’s press release.
BridgeBio Pharma, Inc. (“BridgeBio”) has announced the pricing of its initial public offering of 20,500,000 shares of its common stock at a price to the public of $17.00 per share, as detailed in the company’s press release. In addition, BridgeBio has granted the underwriters a 30-day option to purchase up to 3,075,000 additional shares of its common stock. The shares began trading on the Nasdaq Global Select Market on June 27, 2019, under the ticker symbol “BBIO” and the offering is expected to close on July 1, 2019, subject to customary closing conditions.
Latham & Watkins LLP represents the underwriters in the transaction with a capital markets team led by New York partners Marc Jaffe and Ian Schuman, and Silicon Valley partners Josh Dubofsky and Brian Cuneo with Silicon Valley associates Phillip Stoup, Kaitlyn Fulcher and William Kirton. Advice was also provided on regulatory mattes by Washington, D.C. partners John Manthei and Elizabeth Richards with San Francisco counsel Betty Pang and Washington, D.C. associates Michael Dreyfuss and Nathan Beaton; on intellectual property matters by Silicon Valley partner Christopher Hazuka with San Diego associates Robert Yeh and Brendan Haberle; on tax matters by San Francisco partner Kirt Switzer with associate Jessica Chen.